Organon & Co
(MEX:OGN)
MXN
371
0 (0%)
Market Cap: 97.08 Bil
Enterprise Value: 248.07 Bil
PE Ratio: 4.98
PB Ratio: 108.24
GF Score: 62/100 - Q1 2024 Organon & Co Earnings Call TranscriptMay 02, 2024MXN299Earnings
- Q4 2023 Organon & Co Earnings Call TranscriptFeb 15, 2024MXN270Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2023
- Q3 2023 Organon & Co Earnings Call TranscriptNov 02, 2023MXN281Earnings
- Q2 2023 Organon & Co Earnings Call TranscriptAug 08, 2023MXN360Earnings
- Q1 2023 Organon & Co Earnings Call TranscriptMay 04, 2023MXN425Earnings
- Q4 2022 Organon & Co Earnings Call TranscriptFeb 16, 2023MXN500 (-6.72%)Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Organon & Co at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Q3 2022 Organon & Co Earnings Call TranscriptNov 03, 2022MXN500Earnings
- Q2 2022 Organon & Co Earnings Call TranscriptAug 04, 2022MXN647.72Earnings
- Q1 2022 Organon & Co Earnings Call TranscriptMay 05, 2022MXN663Earnings
- Organon & Co at Cowen Health Care Conference (Virtual) TranscriptMar 09, 2022
- Q4 2021 Organon & Co Earnings Call TranscriptFeb 17, 2022MXN694.06Earnings
- Organon & Co at JPMorgan Healthcare Conference TranscriptJan 10, 2022
- Organon & Co at Evercore ISI HealthCONx Virtual Conference TranscriptDec 01, 2021
- Q3 2021 Organon & Co Earnings Call TranscriptNov 11, 2021MXN670 (-11.48%)Earnings
- Organon & Co at Morgan Stanley Global Healthcare Conference (Fireside Chat) TranscriptSep 13, 2021
- Q2 2021 Organon & Co Earnings Call TranscriptAug 12, 2021MXN668 (+11.52%)Earnings
Organon & Co at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022 / 02:00PM GMT
Release Date Price:
MXN477
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Good morning. Welcome to the 34th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the specialty pharma team, Eric Piper. Our next company, fireside chat is Organon and we're delighted to have Kevin Ali, CEO and Matt Walsh, CFO. Thanks so much for joining us and lots to talk about. So, let's just dive right in if that's okay.
Kevin Ali
Organon & Co. - CEO & Director
Sure.
Questions & Answers
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst
So, I like to start off with a couple of high level questions. And the first is, as we move into '23 -- and I know you get this a lot, what are your biggest priorities in terms of BD M&A? More specifically, is the goal to bolster the pipeline or a commercial stage assets or mix of both?
And the reason I started there is, I guess, it's something that you've talked about a lot on in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)